NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

0.4500 +0.0622 (+16.04%)

As of 10:29:00 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate

PR Newswire 3h ago

RDHL
+16.04%
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

PR Newswire 14d ago

RDHL
+16.04%
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

Insider Monkey 1mo ago

RDHL
+16.04%
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

CNW Group 2mo ago

RDHL
+16.04%
APTX.TO
RedHill Biopharma Announces Up To $19.4 Million Private Placement

PR Newswire 4mo ago

RDHL
+16.04%
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

PR Newswire 4mo ago

RDHL
+16.04%
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

PR Newswire 4mo ago

RDHL
+16.04%
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

PR Newswire 3mo ago

ABVX

MRK

RDHL
+16.04%
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

PR Newswire 1mo ago

RDHL
+16.04%
HYL
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

GlobeNewswire 2mo ago

RDHL
+16.04%
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

PR Newswire 2mo ago

RDHL
+16.04%
HYL
Redhill Biopharma Stock Doubles In One Session — Here's Why

Benzinga 2mo ago

RDHL
+16.04%

Performance Overview

Return	RDHL	MSCI WORLD (^990100-USD-STRD)
YTD	-57.17%	+10.63%
1-Year	-66.07%	--
3-Year	-95.87%	+71.82%

U.S. markets close in 5h 29m

RedHill Biopharma Ltd. (RDHL)

Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Redhill Biopharma Stock Doubles In One Session — Here's Why